Literature DB >> 20542653

Synthesis and characterization of liquid chromatographic columns containing the immobilized ligand binding domain of the estrogen related receptor alpha and estrogen related receptor gamma.

M Sanghvi1, R Moaddel, C Frazier, I W Wainer.   

Abstract

The ligand binding domains of the estrogen related receptors, ERRalpha and ERRgamma were covalently immobilized onto the surface of an aminopropyl silica liquid chromatography stationary phase to create the ERRalpha-silica and ERRgamma-silica columns and onto the surface of open tubular capillaries to create the ERRalpha-OT and ERRgamma-OT columns. The ERR-silica and ERR-OT columns were characterized using frontal chromatographic techniques with diethylstibesterol and the binding affinities, K(d) values, to the immobilized receptors were consistent with the values obtained by a radioligand binding assay. The ERRgamma-silica column was also characterized using non-linear chromatographic techniques using a series of tamoxifen derivatives. The relative K(d) values obtained for the derivatives were consistent with the relative ability of the compounds to inhibit the cellular proliferation of the human-derived T98G glioma cell line, expressed as IC(50) values. The results indicate that the columns containing immobilized ERRalpha and ERRgamma can be created and used to characterize the binding of compounds to the immobilized receptors and that the relative retention of compounds on these columns reflects the magnitude of their inhibitory activity. Published by Elsevier B.V.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20542653      PMCID: PMC2932438          DOI: 10.1016/j.jpba.2010.05.016

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  15 in total

Review 1.  Immobilized receptor- and transporter-based liquid chromatographic phases for on-line pharmacological and biochemical studies: a mini-review.

Authors:  Ruin Moaddel; Lili Lu; Michael Baynham; Irving W Wainer
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2002-02-25       Impact factor: 3.205

2.  Agents with selective estrogen receptor (ER) modulator activity induce apoptosis in vitro and in vivo in ER-negative glioma cells.

Authors:  Ai-Min Hui; Wei Zhang; Wei Chen; Dan Xi; Benjamin Purow; Glenn C Friedman; Howard A Fine
Journal:  Cancer Res       Date:  2004-12-15       Impact factor: 12.701

3.  Diagnostic, treatment, and demographic factors influencing survival in a population-based study of adult glioma patients in the San Francisco Bay Area.

Authors:  Margaret Wrensch; Terri Rice; Rei Miike; Alex McMillan; Kathleen R Lamborn; Kenneth Aldape; Michael D Prados
Journal:  Neuro Oncol       Date:  2006-01       Impact factor: 12.300

4.  The synthesis and initial characterization of an immobilized DNA unwinding element binding (DUE-B) protein chromatographic stationary phase.

Authors:  Ruin Moaddel; Gerry B Price; Jean-Marc Juteau; Michael Leffak; Irving W Wainer
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2005-04-25       Impact factor: 3.205

5.  The preparation and development of cellular membrane affinity chromatography columns.

Authors:  Ruin Moaddel; Irving W Wainer
Journal:  Nat Protoc       Date:  2009       Impact factor: 13.491

6.  Interaction of noncompetitive inhibitors with an immobilized alpha3beta4 nicotinic acetylcholine receptor investigated by affinity chromatography, quantitative-structure activity relationship analysis, and molecular docking.

Authors:  Krzysztof Jozwiak; Sarangan Ravichandran; Jack R Collins; Irving W Wainer
Journal:  J Med Chem       Date:  2004-07-29       Impact factor: 7.446

7.  Deuterium isotope effect on denitrosation and demethylation of N-nitrosodimethylamine by rat liver microsomes.

Authors:  D Wade; C S Yang; C J Metral; J M Roman; J A Hrabie; C W Riggs; T Anjo; L K Keefer; B A Mico
Journal:  Cancer Res       Date:  1987-07-01       Impact factor: 12.701

8.  Development and characterization of immobilized human organic anion transporter-based liquid chromatographic stationary phase: hOAT1 and hOAT2.

Authors:  T Kimura; J Perry; N Anzai; J B Pritchard; R Moaddel
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2007-10-16       Impact factor: 3.205

Review 9.  Changing paradigms--an update on the multidisciplinary management of malignant glioma.

Authors:  Roger Stupp; Monika E Hegi; Martin J van den Bent; Warren P Mason; Michael Weller; René O Mirimanoff; J Gregory Cairncross
Journal:  Oncologist       Date:  2006-02

10.  Initial synthesis and characterization of an immobilized heat shock protein 90 column for online determination of binding affinities.

Authors:  Michał P Marszałł; Ruin Moaddel; Krzysztof Jozwiak; Michel Bernier; Irving W Wainer
Journal:  Anal Biochem       Date:  2007-11-06       Impact factor: 3.365

View more
  4 in total

1.  The cannabinoid receptor inverse agonist AM251 regulates the expression of the EGF receptor and its ligands via destabilization of oestrogen-related receptor α protein.

Authors:  J L Fiori; M Sanghvi; M P O'Connell; S M Krzysik-Walker; R Moaddel; M Bernier
Journal:  Br J Pharmacol       Date:  2011-10       Impact factor: 8.739

Review 2.  The development and characterization of protein-based stationary phases for studying drug-protein and protein-protein interactions.

Authors:  Mitesh Sanghvi; Ruin Moaddel; Irving W Wainer
Journal:  J Chromatogr A       Date:  2011-05-27       Impact factor: 4.759

Review 3.  Targeting Anti-Cancer Active Compounds: Affinity-Based Chromatographic Assays.

Authors:  Marcela Cristina de Moraes; Carmen Lucia Cardoso; Cláudia Seidl; Ruin Moaddel; Quezia Bezerra Cass
Journal:  Curr Pharm Des       Date:  2016       Impact factor: 3.116

4.  Synthesis and characterization of a SIRT6 open tubular column: predicting deacetylation activity using frontal chromatography.

Authors:  Nagendra Singh; Sarangan Ravichandran; Darrell D Norton; Sebastian D Fugmann; Ruin Moaddel
Journal:  Anal Biochem       Date:  2013-01-29       Impact factor: 3.365

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.